memo-inOncology – SPECIAL ISSUE
Find out the latest news from international oncology congresses and stay at the forefront of clinical innovation and advances in lung cancer research. Each SPECIAL ISSUE – CONGRESS REPORT features informative summaries of key topics from lung cancer to come out of a major international oncology congress.
The memo inOncology Medical education series: keeping oncologists at the forefront of lung cancer research. memo – inOncology Special Issue Preceptorship reports summarise the latest in lung cancer research and treatments to come out of our sponsored Preceptorship meeting series. The Fundamentals of Designing Clinical Trials series arms oncologists with the information they need to plan and conduct an oncology trial.
REGISTER
Get a notification for every published memo – inOncology SPECIAL ISSUE. Register below.
LATEST NEWS
memo – inOncology SPECIAL ISSUE
Congress Report virtual ASCO 2021
Report from the ASCO Virtual Congress, 4th–8th June 2021
memo – inOncology SPECIAL ISSUE
Congress Report virtual ASH 2020
The memoinOncology ASH 2020 congress report summarizes highlights from the latest clinical trials in B-Cell malignancies, with a focus on BTK inhibition and PD-1 inhibition. Indications include chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), Waldenström’s macroglobulinemia, marginal zone lymphoma (MZL) and mantle cell lymphoma (MCL), as well as other B-cell malignancies.
All videointerviews from virtual ASCO 2021
Martin Reck compares the combination of novel immune checkpoint inhibitors with other drug classes to monotherapy in terms of efficacy and tolerability, discusses the role of biomarkers and the tumor microenvironment in terms of treatment decision and focuses on the potential predictive value of immune-related adverse events.
David T. Cooke talks about health equity and health disparities relating to lung cancer management in the western world. He explains which factors based on ethnicity are likely to affect outcomes of lung cancer patients and how health disparities might be tackled in the long run at the public health level.
Donald R. Harvey discusses lung cancer from the point of view of clinical pharmacology, targets in the area of antibody-drug conjugates, the role of proteolysis targeting chimeras (PROTACs) in the treatment landscape, highlights mechanisms of resistance to small molecule inhibitors and draws attention to clinical trial design to better meet the demands of modern drug development.
Peter R. Galle overviews the role of immunotherapy in the setting of hepatocellular carcinoma as well as biomarker-based patient selection and discusses which novel combinations of immune checkpoint inhibitors with other drug classes are most promising at present and how those novel strategies impact the treatment landscape.
Ferdinandos Skoulidis summarizes why the development of KRASG12C targeted therapies failed in the past, relates to new developments in the field of KRASG12C inhibition especially sotorasib and discusses the impact of co-mutations on personalized anticancer therapy.
